Impact of Boost Radiation in the Treatment of Ductal Carcinoma In Situ: A Population-Based Analysis

The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies

“…Of them, 29 studies were considered as potentially eligible, while 12 met the C. Nilsson, A. Valachis / Radiotherapy and Oncology 114 (2015) 50-55 51 inclusion criteria for the present study [25][26][27][28][29][30][31][32][33][34][35][36]. One additional eligible study that was presented only in scientific meeting was included in the meta-analysis [37].…”

“…Twelve studies (6943 patients) presented data on local recurrences in patients with DCIS who received boost compared with those who did not receive boost [25,26,[28][29][30][31][32][33][34][35][36][37]. No difference in the risk of local recurrence was observed (OR: 0.91, 95% CI: 0.77-1.08, p = 0.28) (see Fig.…”

“…Six studies presented separate data on the value of boost in patients with positive margins (811 patients) [25,26,28,30,35,37]. Four studies [25,28,30,37] presented data on local recurrence between positive and negative margins whereas two studies [26,35] compared the rate of local recurrences between positive or close (defined as <1-2 mm) and negative margins.…”

“…Four studies [25,28,30,37] presented data on local recurrence between positive and negative margins whereas two studies [26,35] compared the rate of local recurrences between positive or close (defined as <1-2 mm) and negative margins. Patients with positive margins after surgery who received boost radiotherapy had a reduced risk for local recurrence compared to patients with positive margins without boost radiation (OR: 0.56, 95% CI: 0.36-0.87, p = 0.01).…”

“…The role of boost in younger patients (<50 years old) was addressed in 7 studies (1345 patients) [25,26,[29][30][31]35,37]. No difference in the risk for local recurrence with the addition of boost in younger patients was observed (OR: 0.83, 95% CI: 0.62-1.11, p = 0.22).…”